Concarlo Therapeutics Patents

Patent portfolio assigned to Concarlo Therapeutics (verified via public assignee records). Estimated patent count: 3. Concarlo Therapeutics (Brooklyn, NY; founded 2016) - preclinical precision-oncology biotech; lead p27 inhibitor IpY for drug-resistant cancers. Patents confirmed: US20230293643A1 'Brk peptides and methods of use' (assigned to Concarlo Holdings/Therapeutics), WO2015175965A1 (p27Kip1/BRK interaction compositions), plus a US patent issued July 2020 for the therapeutic peptide. No customers/competitors applicable (preclinical biotech).